Online citations, reference lists, and bibliographies.
← Back to Search

Sarcomatoid Mesothelioma: A Clinical–pathologic Correlation Of 326 Cases

S. Klebe, Noel A. Brownlee, A. Mahar, J. Burchette, T. Sporn, R. Vollmer, V. Roggli
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Sarcomatoid mesothelioma is the least common, but most aggressive of the three major histological types of mesotheliomas. This study comprises 326 cases of sarcomatoid mesotheliomas among 2000 consecutive malignant mesothelioma cases received in consultation (16%). Patients included 312 men (96%) and 14 women (4%), with a median age of 70 years (range 41–94 years). Most tumors were pleural (319; 98%), and 7 were peritoneal (2%). Some desmoplastic features were identified in 110 cases (34%), and 70 (21%) were classified as desmoplastic. Rare subtypes included two cases with a lymphohistiocytoid pattern (<1%) and eight heterologous mesotheliomas (2%). Labeling for cytokeratins (CKs) was observed in 261/280 cases (93%), and for calretinin and vimentin in 31 and 91%, respectively. Pleural plaques were present in 79% of cases for which information was available, and asbestosis was diagnosed in 34/127 cases (27%). Median survival was 3.5 months. Fiber analysis was performed in 61 cases. The median asbestos body count was 1640/g wet lung tissue (by light microscopy). Amosite fibers were the most commonly identified fibers using energy-dispersive X-ray analysis and were significantly higher in the sarcomatoid cases, as were uncoated fibers using scanning electron microscopy. This study represents the largest series of sarcomatoid and desmoplastic malignant mesotheliomas to date and confirms the diagnostic usefulness of CK immunohistochemistry. The relationship with asbestos exposure—particularly amosite—and an association with pleural plaques and less often asbestosis is confirmed.
This paper references
10.1097/00000478-199609000-00001
Calretinin: a novel immunocytochemical marker for mesothelioma.
C. Doglioni (1996)
10.1093/AJCP/92.5.566
Immunohistochemical differentiation of sarcomatoid mesotheliomas from other spindle cell neoplasms.
P. Cagle (1989)
10.3109/01913128809064207
Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma.
D. Henderson (1988)
Malignant mesothelio
AJ Moore (2008)
10.1097/01.pas.0000147401.95391.9a
Primary Intrathoracic Synovial Sarcoma: A Clinicopathologic Study of 40 t(X;18)-Positive Cases From the French Sarcoma Group and the Mesopath Group
H. Bégueret (2005)
10.1007/978-3-642-60049-4
Histological Typing of Lung and Pleural Tumours
W. Travis (1999)
10.1046/j.1365-2559.2000.00981.x
Anti‐mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms
R. Attanoos (2000)
10.1111/j.1365-2559.1992.tb00430.x
Intermediate filament expression in mesotheliomas: leiomyoid mesotheliomas are not uncommon
F. Mayall (1992)
7.Desmoplastic Diffuse Malignant Mesotheliomaの1例(第77回 中部肺癌学会)
姫野 一成 (2000)
10.1097/00000478-198204000-00003
Desmoplastic diffuse mesothelioma
R. Cantin (1982)
10.1007/b97620
Pathology of Asbestos-Associated Diseases
V. Roggli (2004)
patients with malignant pleural mesothelioma
V Neumann (1987)
10.5271/SJWEH.226
Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution.
A. Tossavainen (1997)
10.2307/2344557
Nonparametric Statistical Methods.
M. Knott (1974)
10.1038/modpathol.2008.125
Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review
S. Klebe (2008)
10.1097/00000478-200105000-00007
Calretinin and Other Mesothelioma Markers in Synovial Sarcoma: Analysis of Antigenic Similarities and Differences With Malignant Mesothelioma
M. Miettinen (2001)
10.1080/01913120252959227
Malignant Mesothelioma and Occupational Exposure to Asbestos: A Clinicopathological Correlation of 1445 Cases
V. Roggli (2002)
10.1016/j.disamonth.2010.12.003
Benign asbestos-related pleural disease.
Christopher King (2011)
10.1093/AJCP/110.2.191
The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining.
W. E. Mangano (1998)
Tumors of the Serosal Membranes
A. Churg (2006)
Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications.
M. Carbone (2002)
10.1007/978-3-642-41193-9_9
Cytopathology of Asbestos-Associated Diseases
F. Schneider (2004)
10.1136/oem.43.1.18
Asbestos content of lung tissue in asbestos associated diseases: a study of 110 cases.
V. Roggli (1986)
The History of Mesothelioma in Australia 1945-2001
J. Leigh (2002)
10.1056/NEJM198206173062403
The pathogenesis of asbestos-associated diseases.
J. Craighead (1982)
Pathology of human mesothelioma. Etiologic and diagnostic considerations.
V. Roggli (1987)
10.1136/jcp.45.4.295
Desmoplastic malignant mesothelioma: a review of 17 cases.
G. Wilson (1992)
10.1097/00000478-198810000-00002
Three Types of Spindle Cell Tumors of the Pleura: Fibroma, Sarcoma, and Sarcomatoid Mesothelioma
D. Carter (1988)
10.1007/S004200100240
Malignant mesothelioma – German mesothelioma register 1987–1999
V. Neumann (2001)
10.1016/S0031-3025(16)34974-1
Pathology of Lung Tumors
Harold D. Attwood (1998)
10.1007/978-0-387-72114-9_12
Neoplasms of the Pleura
S. Hammar (2008)
10.1016/S0046-8177(88)80529-X
Keratin protein immunoreactivity of sarcomatoid and mixed types of diffuse malignant mesothelioma: an immunoperoxidase study of 30 cases.
A. Montag (1988)
10.1046/j.1365-2559.2003.01583.x
Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study
D. Lucas (2003)
The pathology of mesothelioma, including immunohistology and ultrastructure
DW Henderson (1992)
10.1016/S0012-3692(16)47126-6
Primary Monophasic Synovial Sarcoma of the Pleura
Safdar G. Khan (2004)
10.1097/00000478-200009000-00001
The separation of benign and malignant mesothelial proliferations.
A. Churg (2000)
Unusual histological types and anatomic sites of mesothelioma
DW Henderson (1992)
10.1016/0169-5002(94)92126-1
Pathology of malignant mesothelioma.
E. V. Van marck (2004)
Pleomorphic malignant mesothelio
DW Henderson (2002)
10.1002/PATH.1711670308
‘Pleural’ and pulmonary carcinosarcomas
F. Mayall (1992)
Synovial sarcoma of the pleura: report of four cases.
M. Praet (2002)
10.1016/S0169-5002(01)00257-4
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
G. Ceresoli (2001)
10.1007/978-3-662-09515-7
Progress in Surgical Pathology
Volumexii (1992)
10.1186/1750-1172-3-34
Malignant mesothelioma
A. Moore (2008)
10.1007/978-1-84628-012-2
Pathology of Malignant Mesothelioma
F. Galateau-Sallé (2006)
10.1007/0-387-28274-2_36
Diagnosis of Synovial Sarcoma of the Pleura and Differentiation from Malignant Mesothelioma
A. Powers (2005)
diffuse mesothelioma
S Neragi-Miandoab (1982)
Malignant mesothelioma of the pleura: current surgical pathology
DW Henderson (1997)
10.1016/j.ijsu.2008.04.004
Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
S. Neragi-Miandoab (2008)
Malignant mesotheliomas with osseous and cartilaginous differentiation.
S. Yousem (1987)
Pleomorphic malignant mesothelioma
DW Henderson (2002)
10.1097/PAS.0b013e31814faacf
Podoplanin is a Better Immunohistochemical Marker for Sarcomatoid Mesothelioma Than Calretinin
Diana M Padgett (2008)



This paper is referenced by
10.1186/s12931-020-01449-2
Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression
M. Kojima (2020)
Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma.
K. Pillai (2013)
10.1097/PAS.0000000000000825
GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung
Kyra B. Berg (2017)
Risk factors and biomarkers for malignant mesothelioma
Vasiliki Panou (2019)
10.1007/978-3-642-02322-4_43
Tumoren und tumorartige Läsionen des Peritoneums
F. Offner (2013)
10.3390/cancers12040939
S100A4 Is a Biomarker of Tumorigenesis, EMT, Invasion, and Colonization of Host Organs in Experimental Malignant Mesothelioma
Joëlle S. Nader (2020)
10.18632/oncotarget.15744
Evaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma.
D. Pouliquen (2017)
10.21037/tlcr.2019.11.29
Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
D. Chapel (2020)
10.1093/omcr/omu021
Desmoplastic malignant mesothelioma of the peritoneum
B. Badak (2014)
Aspects épidémiologiques, cliniques et histopathologiques du mésothéliome malin myxoïde : à propos d’une étude de 140 cas
O. Stephanov (2016)
10.1016/j.humpath.2017.07.015
The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
A. Marchevsky (2017)
Aspects cliniques et histopathologiques du mésothéliome pleural malin chez l’enfant et l’adulte jeune : à propos d’une série de 47 cas
Christelle Combaz-Lair (2015)
10.1186/s12885-016-2745-8
Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review
K. Hashimoto (2016)
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma
Aliya N. Husain (2017)
10.1016/j.humpath.2020.08.005
The potential utility of GATA3 for diagnosis of malignant pleural mesotheliomas.
Sarita Prabhakaran (2020)
10.3109/01913123.2016.1170085
Asbestos content of lung tissue in patients with malignant peritoneal mesothelioma: A study of 42 cases
G. D. de Ridder (2016)
10.1093/jnci/djs513
Pleural plaques and the risk of pleural mesothelioma.
J. Pairon (2013)
10.1016/j.pathol.2016.07.009
Vasculogenic mimicry in malignant mesothelioma: an experimental and immunohistochemical analysis.
E. Pulford (2016)
Pleural Malignant Mesothelioma : Signi fi cant Advances Histologic Subtyping of Epithelioid Mesothelioma
F. Galateau-Sallé (2016)
10.1007/978-3-319-99510-6_2
Pathology of Selected Primary and Metastatic Tumors of Peritoneum
Kozlov A. Nikolay (2019)
10.1002/9781118399668.CH47
Tumours and Tumour‐Like Lesions of the Peritoneum
Richard Luther Attanoos (2012)
10.1111/pin.12226
Sarcomatoid pleural mesothelioma with osteosarcomatous, chondrosarcomatous and rhabdomyoblastic elements: An extremely rare autopsy case
Y. Tsukamoto (2015)
10.1097/PAS.0000000000001418
Malignant Diffuse Mesothelioma in Women
E. Pavlisko (2019)
10.3390/app10010040
Immunohistochemical Expression of Wilms’ Tumor 1 Protein in Human Tissues: From Ontogenesis to Neoplastic Tissues
Lucia Salvatorelli (2019)
10.5858/arpa.2016-0550-RA
Application of Immunohistochemistry in the Diagnosis of Pulmonary and Pleural Neoplasms.
J. Woo (2017)
10.1007/978-1-4471-2825-0_16
Malignant Mesothelioma: Pathology
S. Anttila (2014)
10.5858/arpa.2010-0604-RA
Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
P. Betta (2012)
10.7180/kmj.2019.34.2.146
A Case of Peritoneal Sarcomatoid Mesothelioma with Absence of Occupationl Exposure to Asbestos
Seung Hoon Yoo (2019)
10.1136/oemed-2016-103721
Asbestos exposure and histological subtype of malignant mesothelioma
P. Franklin (2016)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.4081/RT.2010.E46
Sarcomatous malignant peritoneal mesothelioma with large bowel involvement
Tomoaki Kaneko (2010)
10.1634/theoncologist.2018-0501
Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
S. V. Soldera (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar